Skip to content

Prospective, randomized controlled clinical study on the efficacy and safety of human interferon a2b spray in the treatment of asymptomatic patients infected with novel coronavirus Omicron variant

Prospective, randomized controlled clinical study on the efficacy and safety of human interferon a2b spray in the treatment of asymptomatic patients infected with novel coronavirus Omicron variant

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058790
Enrollment
Unknown
Registered
2022-04-17
Start date
2022-04-15
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asymptomatic patients infected with a novel coronavirus Omicron variant

Interventions

Experimental group:Add topical spraying of human interferon a2b solution in the nose and oropharynx to the basic and herbal treatment
Control group:Centralized isolation management, bed rest, application of traditional Chinese medicine, strengthening supportive treatment, ensuring adequate energy and nutrition intake
paying attention to water and electrolyte balance, maintaining a stable internal environment, and closely monitoring vital signs and clinical symptoms.

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years old, male or female; 2. With epidemiological history; 3. Clinically diagnosed as a confirmed case of novel coronavirus infection, the diagnostic criteria are in accordance with the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial ninth Edition); including: (1) The novel coronavirus nucleic acid test is positive; (2) No clinical symptoms; (3) There is no evidence of pneumonia in imaging; 4. No other antiviral drugs and immunomodulatory preparations were used within one week before the diagnosis.

Exclusion criteria

Exclusion criteria: 1. Those who are known to be allergic to interferon; 2. Lupus erythematosus, psoriasis and other autoimmune diseases or immunodeficiency diseases; 3. People with chronic underlying diseases at risk of developing into severe patients, late pregnancy and perinatal women, etc.; 4. Those with epilepsy or other central nervous system dysfunction; 5. Mixed infections with bacteria and other pathogens in the respiratory tract were determined before enrollment; 6. Those who refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Virus negative conversion time;

Secondary

MeasureTime frame
Virus negative conversion rate;Pneumonia confirmation rate;

Countries

China

Contacts

Public ContactYufeng Gao

The First Affiliated Hospital of Anhui Medical University

aygyf@126.com+86 13956938032

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026